Investigational Drug Information for Verubecestat
What is the drug development status for Verubecestat?
Verubecestat is an investigational drug.
There have been 3 clinical trials for Verubecestat.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 5th 2013.
The most common disease conditions in clinical trials are Alzheimer Disease, Mild Cognitive Impairment, and Cognitive Dysfunction. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Summary for Verubecestat
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 305 |
| WIPO Patent Applications | 74 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2013-11-05) |
| Vendors | 0 |
Recent Clinical Trials for Verubecestat
| Title | Sponsor | Phase |
|---|---|---|
| An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016) | Merck Sharp & Dohme Corp. | Phase 1 |
| Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) | Merck Sharp & Dohme Corp. | Phase 3 |
| An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 |
Clinical Trial Summary for Verubecestat
Top disease conditions for Verubecestat
Top clinical trial sponsors for Verubecestat
US Patents for Verubecestat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Verubecestat Development Update, Patent Position, and Market Projection
Verubecestat is a discontinued investigational beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor developed by Merck & Co. for Alzheimer’s disease. Merck stopped the program after Phase 3 trials failed to show clinical benefit and raised safety concerns. Verubecestat has no FDA approval, no Orange Book listing, no commercial sales, and no credible future prescription-drug market forecast.
What is the current development status of verubecestat?
Verubecestat development is terminated. Merck discontinued the Alzheimer’s disease program after two late-stage studies failed:
| Development program | Population | Trial status | Outcome |
|---|---|---|---|
| EPOCH, NCT01739348 | Mild-to-moderate Alzheimer’s disease | Terminated in 2017 | No slowing of cognitive or functional decline |
| APECS, NCT01953601 | Prodromal Alzheimer’s disease, including mild cognitive impairment | Terminated in 2018 | No clinical benefit and safety concerns |
| Earlier Phase 1 and Phase 2 studies | Healthy volunteers and Alzheimer’s patients | Completed | Target engagement and amyloid reduction did not translate into efficacy |
Merck disclosed in February 2017 that it stopped EPOCH after an interim analysis showed that verubecestat was unlikely to demonstrate benefit on the primary endpoints. The company stopped APECS in June 2018 after an interim analysis found no benefit in prodromal Alzheimer’s disease and identified adverse findings that made continuation inappropriate.[1,2]
The compound is also known as MK-8931. It was designed to inhibit BACE1, the enzyme involved in the first cleavage step that produces beta-amyloid. The development strategy assumed that reducing beta-amyloid production would slow Alzheimer’s disease progression.
Why did verubecestat fail in Phase 3 trials?
Verubecestat reduced cerebrospinal-fluid beta-amyloid biomarkers but did not improve cognition or daily functioning. The clinical failure indicates that biomarker suppression was insufficient to reverse or slow established neurodegenerative disease.
EPOCH trial results
The EPOCH trial evaluated verubecestat in patients with mild-to-moderate Alzheimer’s disease. The study tested once-daily doses against placebo over approximately 18 months.
The trial did not meet its primary efficacy endpoints. Verubecestat failed to improve:
- Cognitive performance, measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale.
- Functional performance, measured by the Alzheimer’s Disease Cooperative Study-Activities of Daily Living inventory.
The published results showed no meaningful clinical improvement despite substantial reduction in beta-amyloid production. Adverse events included weight loss, falls, sleep-related events and neuropsychiatric effects. The results were published in the New England Journal of Medicine in 2018.[1]
APECS trial results
APECS studied patients with prodromal Alzheimer’s disease, a population earlier in the disease course than the EPOCH population. The trial was intended to test whether earlier intervention could produce a better result.
The study was stopped for futility. Verubecestat did not slow cognitive decline compared with placebo. The trial also raised concern about worsening cognition and neuropsychiatric adverse events, including anxiety, depression and sleep disturbance.[2]
The APECS outcome reduced the prospect that changing the treatment population from established Alzheimer’s disease to prodromal disease would rescue the BACE1 mechanism.
What is the FDA regulatory status of verubecestat?
Verubecestat is not FDA-approved and has no approved indication. Merck did not obtain an NDA approval for Alzheimer’s disease, and the compound is not marketed in the United States or other major pharmaceutical markets.
| Regulatory item | Status |
|---|---|
| FDA approval | None |
| Approved indication | None |
| NDA | No marketed approval |
| Orange Book listing | None |
| FDA exclusivity | None |
| U.S. commercial launch | None |
| Biosimilar designation | Not applicable |
| Generic approval pathway | Not commercially relevant |
Because verubecestat is a small molecule that never reached approval, it has no regulatory exclusivity period that could delay generic entry. The product also has no reference-listed drug status in the Orange Book.
What patents protect verubecestat?
Verubecestat was protected during development by Merck-related small-molecule patent filings covering the compound, pharmaceutical compositions and methods of treating Alzheimer’s disease. The practical commercial value of those rights has fallen sharply because the clinical program ended without approval.
Publicly relevant patent categories included:
| Patent category | Likely scope | Commercial position |
|---|---|---|
| Composition-of-matter patents | Verubecestat and related BACE1 inhibitor structures | Core exclusivity during development |
| Pharmaceutical-composition patents | Drug formulations and dosage forms | Limited value after termination |
| Method-of-use patents | Treatment or prevention of Alzheimer’s disease | No marketed indication to enforce |
| Manufacturing patents | Processes and intermediates | Potential technical barriers, but no commercial product |
| Biomarker or patient-selection claims | Use in selected Alzheimer’s populations | Weak market relevance after negative trials |
No Orange Book-listed verubecestat patents exist because the drug was never approved. Patent expiration therefore does not create a conventional generic-entry event. The key commercial date was the end of clinical development, not loss of regulatory exclusivity.
A patent estate may still have legal life in certain jurisdictions, particularly for compound claims, formulations or manufacturing intermediates. Those rights do not create a viable product market without regulatory approval and supporting clinical data.
When did verubecestat lose commercial exclusivity?
Verubecestat did not lose exclusivity through normal patent expiry. It lost commercial development value when Merck terminated the clinical program.
The main timeline is:
| Date | Event |
|---|---|
| 2012-2014 | Phase 1 and Phase 2 development established strong BACE1 target engagement |
| 2014 | Merck initiated the Phase 3 EPOCH trial |
| February 2017 | EPOCH was stopped for futility |
| 2017-2018 | Merck continued evaluation in earlier-stage disease through APECS |
| June 2018 | APECS was stopped after lack of efficacy and safety concerns |
| 2018 onward | Verubecestat development effectively ended |
| Current status | No approval, launch, revenue or active late-stage program |
There is no credible pathway to a standard generic launch because there is no approved reference product. An independent company could theoretically pursue a new drug application using its own clinical program, but the negative Phase 3 evidence makes that scenario commercially remote.
Which companies challenged the verubecestat program?
No major Paragraph IV challenge is associated with verubecestat. Paragraph IV litigation generally arises when a generic applicant seeks FDA approval for a product referencing an approved branded drug and asserts that listed patents are invalid, unenforceable or not infringed.
Verubecestat never reached the approved-product stage. As a result:
- No ANDA-based generic challenge became commercially significant.
- No standard Orange Book patent litigation developed.
- No branded-generic settlement agreement is known to have affected market entry.
- No authorized generic strategy was established.
- No biosimilar challenge applies because verubecestat is a small molecule, not a biologic.
Patent disputes involving development-stage BACE1 compounds could still occur in principle, but they would not constitute a conventional Paragraph IV challenge to a marketed verubecestat product.
How strong is the verubecestat patent estate?
The patent estate was technically meaningful during the development period but commercially weak after clinical failure.
Strengths
Merck had several forms of potential protection:
- A proprietary BACE1 inhibitor structure.
- Patent claims covering therapeutic use.
- Development data supporting an investigational drug profile.
- Manufacturing and formulation know-how.
- Clinical experience across multiple Alzheimer’s disease stages.
Weaknesses
The estate has major commercial limitations:
- No approved indication.
- No Orange Book listing.
- No commercial formulation.
- No demonstrated clinical efficacy.
- No established reimbursement position.
- No durable prescriber base.
- No regulatory exclusivity remaining to protect a launch.
Patent life alone cannot support a meaningful valuation for a discontinued Alzheimer’s drug. The central asset, clinical efficacy, was not established.
What is the market projection for verubecestat?
The projected commercial market for verubecestat is effectively zero under the existing development record.
| Market metric | Projection |
|---|---|
| Current sales | Zero |
| Current marketed patients | Zero |
| FDA-approved revenue opportunity | None |
| Near-term launch probability | Negligible |
| Generic substitution market | None |
| Licensing value as a commercial drug | Low |
| Research or repurposing value | Limited and speculative |
Merck’s Alzheimer’s program was aimed at a large potential market. Alzheimer’s disease affects millions of patients globally, and disease-modifying treatments command significant pricing when they demonstrate clinical benefit. That theoretical market does not transfer to verubecestat because the compound failed its efficacy trials and has no regulatory path based on the existing data.
A future commercial scenario would require a new sponsor to:
- Establish a differentiated mechanism or biomarker-defined population.
- Generate new clinical evidence despite negative Phase 3 results.
- Address neuropsychiatric and cognitive safety concerns.
- Obtain FDA agreement on a viable development plan.
- Fund a new Phase 2 and Phase 3 program.
- Compete against approved anti-amyloid antibodies and future Alzheimer’s therapies.
That risk-adjusted opportunity is substantially inferior to programs with positive clinical data. The likely value of verubecestat is limited to archived development knowledge, mechanism research and possible use as a comparator in BACE1 studies.
How does verubecestat compare with approved Alzheimer’s drugs?
Verubecestat and the leading approved disease-modifying Alzheimer’s therapies address amyloid biology through different mechanisms.
| Drug | Mechanism | Status | Clinical outcome | Commercial position |
|---|---|---|---|---|
| Verubecestat | BACE1 inhibitor that reduces beta-amyloid production | Discontinued | No clinical benefit in Phase 3 | No market |
| Lecanemab | Anti-amyloid beta antibody | FDA-approved | Slows decline in early Alzheimer’s disease | Commercially marketed |
| Donanemab | Anti-amyloid beta antibody | FDA-approved | Slows decline in early Alzheimer’s disease | Commercially marketed |
| Aducanumab | Anti-amyloid beta antibody | FDA-approved with restricted use | Controversial clinical benefit and limited uptake | Limited commercial role |
Lecanemab and donanemab remove selected amyloid plaques after they form. Verubecestat attempted to reduce beta-amyloid generation upstream. The failure of verubecestat does not invalidate all amyloid-directed approaches, but it demonstrates that target engagement and amyloid reduction alone do not establish clinical efficacy.
What generic entry risks exist for verubecestat?
Generic entry risk is minimal because there is no approved product to reference. The more relevant risk is unauthorized development or off-label research use, neither of which creates a conventional pharmaceutical market.
Potential barriers include:
- Merck patent claims that remain unexpired in selected countries.
- Proprietary synthesis and formulation information.
- Lack of validated clinical dosing.
- Negative efficacy data.
- Safety concerns.
- Competition from approved and late-stage Alzheimer’s treatments.
- High cost of renewed clinical development.
A company that synthesized verubecestat after relevant compound patents expired could still face regulatory barriers. Patent freedom to operate would not solve the clinical and approval problems.
What licensing deals and settlement agreements involve verubecestat?
No major commercial licensing transaction, co-development agreement or generic settlement agreement has materially affected verubecestat’s market position. Merck was the principal developer, and the program remained an internal Merck Alzheimer’s effort through its termination.
There is no evidence of:
- A marketed-product license.
- A regional commercialization deal.
- A royalty-bearing partnership tied to approval.
- A Paragraph IV settlement.
- A launch-for-license agreement.
- A biosimilar or follow-on biologic transaction.
Key Takeaways
- Verubecestat, also known as MK-8931, is a discontinued Merck BACE1 inhibitor.
- EPOCH was stopped in 2017 for futility in mild-to-moderate Alzheimer’s disease.
- APECS was stopped in 2018 after no benefit in prodromal Alzheimer’s disease and safety concerns.
- Verubecestat has no FDA approval, Orange Book listing, market exclusivity or commercial revenue.
- No conventional Paragraph IV challenge or generic-entry litigation is associated with the drug.
- Patent rights may remain in certain jurisdictions, but they have little commercial value without clinical efficacy.
- The current market projection is effectively zero.
- Any future development would require a new sponsor, new trials and a revised clinical rationale.
FAQs About Verubecestat
Is verubecestat still being developed?
No. Merck terminated the Alzheimer’s disease program after negative Phase 3 results and did not advance the compound toward approval.
Did verubecestat reduce amyloid in clinical trials?
Yes. Verubecestat reduced beta-amyloid production and related biomarkers, but biomarker activity did not produce a meaningful clinical benefit.
Can verubecestat become a generic drug?
There is no conventional generic pathway because verubecestat was never approved and has no reference-listed drug in the FDA Orange Book.
Is verubecestat a biologic or a small molecule?
Verubecestat is an orally administered small-molecule BACE1 inhibitor. Biosimilar rules do not apply.
Could verubecestat be repurposed for another disease?
A repurposing program is theoretically possible, but the available Alzheimer’s clinical data and safety findings make a commercially significant new indication unlikely without substantial new evidence.
References
-
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., van Dyck, C. H., Boada, M., Budd, S. L., Farris, W., et al. (2018). Randomized trial of verubecestat for prodromal Alzheimer’s disease. New England Journal of Medicine, 378(18), 1691-1703.
-
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019). Randomized trial of verubecestat for prodromal Alzheimer’s disease. New England Journal of Medicine, 380, 1408-1420.
-
Merck & Co., Inc. (2017, February 14). Merck provides update on phase 3 EPOCH trial of verubecestat for treatment of people with mild-to-moderate Alzheimer’s disease. Corporate press release.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2021). FDA grants accelerated approval for Alzheimer’s drug. FDA.
-
U.S. Food and Drug Administration. (2023). FDA converts novel Alzheimer’s disease treatment to traditional approval. FDA.
More… ↓
